New Insight in a New Entity: NIFTPS and Valuable Role of Ancillary Techniques. The Role of PD-L1

Rossi, Esther Diana; Martini, Maurizio

doi:10.1016/j.ebiom.2017.03.035

Cited by 5 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We are cognizant that the limited follow up period (1.5–5 years) did not permit a clear statement regarding the relationship of the observed high PD-L1 expression in some NIFTP and their aggressiveness and/or recurrence. Nevertheless, the differential expression of PD-L1 in the different subgroups was significant and with further studies may support its future use in clinical management as an ancillary aid to a histopathologist report [ 14 ]. With continuing observations on the DIA test and its long term follow up on clinical outcomes, it will be possible using machine learning methods to improve the sensitivity and specificity of this test in the future.…”

Section: Discussionmentioning

confidence: 99%

“…Shi et al independently confirmed the positive correlation of increased PD-L1 expression with PTC recurrence [ 12 ]. Fu et al in our lab recently demonstrated PD-L1 immunohistochemistry (IHC) staining as an ancillary technique in distinguishing invasive EFVPTC from NIFTP and supported the reclassification of NIFTP [ 13 , 14 ] even if the tumor size is more than 4 cm or the patients are older than 45 years of age [ 15 ]. However, all reports to date have relied on manual scoring that is time consuming and can be subject to individual bias.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Programmed death-ligand 1 expression by digital image analysis advances thyroid cancer diagnosis among encapsulated follicular lesions

Hsieh

Polyakova

et al. 2018

Oncotarget

View full text Add to dashboard Cite

Recognition of noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP) that distinguishes them from invasive malignant encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC) can prevent overtreatment of NIFTP patients. We and others have previously reported that programmed death-ligand 1 (PD-L1) is a useful biomarker in thyroid tumors; however, all reports to date have relied on manual scoring that is time consuming as well as subject to individual bias. Consequently, we developed a digital image analysis (DIA) protocol for cytoplasmic and membranous stain quantitation (ThyApp) and evaluated three tumor sampling methods [Systemic Uniform Random Sampling, hotspot nucleus, and hotspot nucleus/3,3′-Diaminobenzidine (DAB)]. A patient cohort of 153 cases consisting of 48 NIFTP, 44 EFVPTC, 26 benign nodules and 35 encapsulated follicular lesions/neoplasms with lymphocytic thyroiditis (LT) was studied. ThyApp quantitation of PD-L1 expression revealed a significant difference between invasive EFVPTC and NIFTP; but none between NIFTP and benign nodules. ThyApp integrated with hotspot nucleus tumor sampling method demonstrated to be most clinically relevant, consumed least processing time, and eliminated interobserver variance. In conclusion, the fully automatic DIA algorithm developed using a histomorphological approach objectively quantitated PD-L1 expression in encapsulated thyroid neoplasms and outperformed manual scoring in reproducibility and higher efficiency.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Programmed death-ligand 1 expression by digital image analysis advances thyroid cancer diagnosis among encapsulated follicular lesions

Hsieh

Polyakova

et al. 2018

Oncotarget

View full text Add to dashboard Cite

show abstract

“…The majority of studies examining PD-1 ligands in thyroid cancer have been aimed at evaluation of their prognostic relevance by correlating the expression levels with patients’ clinicopathological features, while some studies have attempted to estimate the diagnostic value of PD-1 ligands in thyroid cancer [42,69,70,71]. Cunha and colleagues, by means of IHC analysis of 293 DTC, 114 benign thyroid lesions and 5 normal tissues, found that PD-L1 protein did not have a diagnostic utility [42].…”

Section: Expression and Clinical Utility Of Pd-1 Ligands In Thyroimentioning

confidence: 99%

“…Cunha and colleagues, by means of IHC analysis of 293 DTC, 114 benign thyroid lesions and 5 normal tissues, found that PD-L1 protein did not have a diagnostic utility [42]. However, more recently, it has been reported that PD-L1 expression may help to distinguish aggressive forms of encapsulated FVPTC (EFVPTC) from the noninvasive ones, reclassified as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) at low risk of malignancy [69,70,71,72]. In particular, Fu and colleagues retrospectively analyzed the expression of PD-L1, by means of IHC, in 52 NIFTP and 45 invasive EFVPTC in comparison with 40 benign nodules [66,67].…”

Section: Expression and Clinical Utility Of Pd-1 Ligands In Thyroimentioning

confidence: 99%

“…In particular, Fu and colleagues retrospectively analyzed the expression of PD-L1, by means of IHC, in 52 NIFTP and 45 invasive EFVPTC in comparison with 40 benign nodules [66,67]. The authors found no significant differences in PD-L1 cytoplasmic staining between NIFTP and thyroid benign lesions, while a considerable increase was observed between NIFTP or benign lesion and invasive FVPTC [69,70,71]. Since the majority of NITPF are diagnosed as indeterminate lesions in clinical practice [73,74], the opportunity to discriminate NIFTP from invasive EFVPTC based on PD-L1 assessment should improve the diagnostic accuracy and the clinical management of these patients, reducing the number of those undergoing surgical overtreatment.…”

Section: Expression and Clinical Utility Of Pd-1 Ligands In Thyroimentioning

confidence: 99%

See 1 more Smart Citation

PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications

Ulisse

Tuccilli

Sorrenti

et al. 2019

IJMS

View full text Add to dashboard Cite

The new immunotherapy targeting the programmed cell death 1 (PD-1) receptor and its cognate ligand PD-L1 has renewed hopes of eradicating the most difficult human cancers to treat. Among these, there are the poorly differentiated and anaplastic thyroid cancers, unresponsive to all the therapies currently in use. In the present review we will summarize information regarding the expression of PD-L1 in the different thyroid cancer histotypes, its correlation with clinicopathological features, and its potential prognostic value. Then, we will evaluate the available data indicating the PD-1/PD-L1 axis as a promising target for thyroid cancer therapy.

show abstract

Revised criteria for diagnosis of NIFTP reveals a better correlation with tumor biological behavior

Paniza

Mendes

Viana

et al. 2019

Endocrine Connections

View full text Add to dashboard Cite

The recent reclassification of a follicular variant of papillary thyroid carcinoma (FVPTC), subset as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), aims to avoid overtreatment of patients with an indolent lesion. The diagnosis of NIFTP has recently been revisited using more rigid criteria. This study presents histological and molecular findings and a long clinical follow-up of 94 FVPTC, 40 cases of follicular adenoma (FTA) and 22 cases of follicular carcinoma (FTC) that were classified before the advent of the NIFTP reclassification. All slides were reviewed using these rigid criteria and analysis of numerous sections of paraffin blocks and reclassified as 7 NIFTPs, 2 EFVPTCs, 29 infiltrative FVPTC (IFVPTCs), 57 invasive EFVPTC (I-EFVPTCs), 39 FTAs and 22 FTCs. Remarkably, EFVPTC and NIFTP patients were all free of disease at the end of follow-up and showed no BRAF mutation. Only one NIFTP sample harbored mutations, an NRAS Q61R. PAX8/PPARG fusion was found in I-EFVPTCs and FTC. Although additional studies are needed to identify a specific molecular profile to aid in the diagnosis of lesions with borderline morphological characteristics, we confirmed that the BRAF V600E mutation is an important tool to exclude the diagnosis of NIFTP. We also show that rigorous histopathological criteria should be strongly followed to avoid missing lesions in which more aggressive behavior is present, mainly via the analysis of capsule or vascular invasion and the presence of papillary structures.

show abstract

New Insight in a New Entity: NIFTPS and Valuable Role of Ancillary Techniques. The Role of PD-L1

Cited by 5 publications

References 10 publications

Programmed death-ligand 1 expression by digital image analysis advances thyroid cancer diagnosis among encapsulated follicular lesions

Programmed death-ligand 1 expression by digital image analysis advances thyroid cancer diagnosis among encapsulated follicular lesions

PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications

Revised criteria for diagnosis of NIFTP reveals a better correlation with tumor biological behavior

Contact Info

Product

Resources

About